MDRO Reporting

Carbapenem-Resistant Enterobacteriaceae (CRE)

When:  July 2018

What:  Reporting and submitting isolates within 7 days for Carbapenem-Resistant Enterobacterales (CRE) defined as any Klebsiella spp., Enterobacter spp., or Escherichia coli that is resistant to carbapenems or that produces carbapenemase; see  Laboratory CRE Reporting and Submission Guidelines  .

(Note: Reporting and submission of other healthcare-associated carabapenamse-resistant organism isolates, including other CR-genera in the order, Enterobacterales, CR-Pseudomonas spp., and CR-Acinetobacter spp., is strongly encouraged but not required; contact [email protected] for more information.)

Laboratories can report via electronic laboratory reporting, secure email to [email protected] within 7 days.

Patient information can be entered into the CRE case report form in SendSS. 

To create a SendSS authorized user account, complete a registration form at https://sendss.state.ga.us/sendss/ords/login.screen.

For SendSS related questions, please email: [email protected].

CRE Isolate Submission

• Click here:    GPHL CRE/ARLN Sentinel Laboratory Submission Form 
• Click here:    Category B Shipping Guidance
• Click here:    Laboratory CRE Reporting and Submission Guidelines

Background and Justification:

http://www.cste.org/resource/resmgr/2015PS/2015PSFinal/15-ID-05.pdf

https://cdn.ymaws.com/www.cste.org/resource/resmgr/2017PS/2017PSFinal/17-ID-04.pdf

Candida auris: Call for Cases

Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality. C. auris can spread from patient to patient within healthcare facilities and cause prolonged healthcare-associated outbreaks.

C. auris can be misidentified as a number of different organisms when using traditional phenotypic methods for yeast identification.

When to suspect C. auris: https://www.cdc.gov/fungal/candida-auris/recommendations.html

Healthcare facilities or laboratories that suspect they have a patient with C. auris infection should contact the HAI team at GDPH ([email protected] or 404-657-2588) and CDC ([email protected]) immediately for guidance.

Background and Justification:

http://www.cste.org/resource/resmgr/2017PS/2017PSFinal/17-ID-03.pdf